These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 14574325)

  • 1. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia.
    Breccia M; Latagliata R; Carmosino I; Mandelli F; Alimena G
    Leukemia; 2004 Jan; 18(1):182. PubMed ID: 14574325
    [No Abstract]   [Full Text] [Related]  

  • 2. Precipitation of porphyria cutanea tarda by imatinib mesylate?
    Ho AY; Deacon A; Osborne G; Mufti GJ
    Br J Haematol; 2003 Apr; 121(2):375. PubMed ID: 12694262
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib mesylate-induced pseudoporphyria.
    Berghoff AT; English JC
    J Am Acad Dermatol; 2010 Jul; 63(1):e14-6. PubMed ID: 20542169
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract]   [Full Text] [Related]  

  • 6. [Management of chronic myeloid leukemia by imatinib].
    Kizaki M
    Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
    Mcpherson T; Sherman V; Turner R
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
    Langabeer SE; Crampe M; Haslam K; Kelly J; Cahill MR
    Leuk Res; 2010 Jul; 34(7):e176-7. PubMed ID: 20153526
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 10. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
    Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
    Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
    Smith BD
    J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical management of patients with chronic myeloid leukemia receiving imatinib.
    Deininger MW; O'Brien SG; Ford JM; Druker BJ
    J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of imatinib as frontline therapy for chronic myeloid leukemia.
    Marin D
    Semin Hematol; 2010 Oct; 47(4):312-8. PubMed ID: 20875547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
    Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity of imatinib: At the heart of the problem.
    Tiribelli M; Medeot M
    Leuk Res; 2011 Jan; 35(1):36-7. PubMed ID: 20970188
    [No Abstract]   [Full Text] [Related]  

  • 16. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
    Breccia M; Alimena G
    Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
    [No Abstract]   [Full Text] [Related]  

  • 17. Gleevec (STI-571) for chronic myeloid leukemia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):49-50. PubMed ID: 11402258
    [No Abstract]   [Full Text] [Related]  

  • 18. STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.
    Kumar L; Kumari M; Menon H
    Natl Med J India; 2002; 15(5):298. PubMed ID: 12502149
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Drummond MW; Holyoake TL
    Cancer; 2003 Oct; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.